Mounjaro and Ozempic are two medications that can help with diabetes and weight management. But is there a winner in the ...

We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

WeightWatchers has filed for bankruptcy in the US as it struggles with debt and fierce competition from fat-loss jabs like ...

The legal process will see $1.15bn (£860mn) of the 60-year-old diet brand's debt written off while it agrees new terms for ...

Diageo's share price has dropped 15.3% in the year to date. Could it be about to become one of the FTSE 100's best recovery ...